OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Jacobs Discusses the Frontline Treatment of CLL

May 15th 2018

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the frontline treatment of patients with chronic lymphocytic leukemia.

Dr. Verma on Immunotherapy in HER2+ Breast Cancer

May 14th 2018

Sunil Verma, MD, professor and head of the Department of Oncology at the University of Calgary, medical director of the Tom Baker Cancer Centre, discusses immunotherapy in HER2-positive breast cancer.

Dr. Ginsburg on Cervical Cancer Disparities in Low-Income Countries

May 14th 2018

Ophira Ginsburg, MD, director of the High Risk/Cancer Genetics Program at NYU Langone's Perlmutter Cancer Center, discusses cervical cancer disparities in low-income countries.

Dr. Choyke on Combining Imaging Techniques in Prostate Cancer

May 14th 2018

Peter L. Choyke, MD, FACP, director, Molecular Imaging Program, head, Imaging Section, Center for Cancer Research, National Cancer Institute, discusses the combination of imaging techniques in prostate cancer.

Dr. Hellmann on Tumor Mutational Burden Testing in Patients With Lung Cancer

May 12th 2018

Matthew D. Hellmann, MD, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses the process of tumor mutational burden (TMB) testing in patients with lung cancer.

Dr. Borad on the SARAH and SIRveNIB Studies in Hepatocellular Carcinoma

May 12th 2018

Mitesh J. Borad, MD, associate professor of medicine, consultant, Division of Hematology/Oncology, Mayo Clinic, discusses the results of the SARAH and SIRveNIB studies in patients with hepatocellular carcinoma.

Dr. Ahn on the Role of Immunotherapy in Treating Patients With Gastric/Gastroesophageal Cancers

May 11th 2018

Daniel H. Ahn, DO, oncologist and internist, Mayo Clinic, discusses the role of immunotherapy in treating patients with gastric/gastroesophageal cancers.

Dr. Patel Discusses Impact of Immunotherapy on NSCLC

May 11th 2018

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses the impact of immunotherapy on the treatment of patients with non–small cell lung cancer.

Dr. Pegram Discusses Adjuvant Pertuzumab in HER2+ Breast Cancer

May 11th 2018

Mark D. Pegram, MD, Susy Yuan-Huey Hung Professor, co-director, Stanford’s Molecular Therapeutics Program, director, Breast Cancer Oncology Program, Stanford Women’s Cancer Center, discusses the use of adjuvant pertuzumab (Perjeta) in patients with HER2-positive breast cancer.

Dr. Costales on Study of Adjuvant Therapy in Uterine Leiomyosarcoma

May 11th 2018

Anthony Costales, MD, gynecologic oncology fellow, Cleveland Clinic, discusses a study of adjuvant therapy for patients with uterine leiomyosarcoma.

Dr. Balar on Impact of Durvalumab Plus Tremelimumab in Bladder Cancer

May 10th 2018

Arjun V. Balar, MD, assistant professor, Department of Medicine, director, Genitourinary Medical Oncology Program, NYU Langone’s Perlmutter Cancer Center, discusses the impact of the combination of durvalumab (Imfinzi) plus tremelimumab in metastatic bladder cancer.

Dr. Kirson Discusses the LUNAR Study in Advanced NSCLC

May 10th 2018

Eilon Kirson, MD, PhD, chief medical officer, Novocure, discusses the LUNAR study in advanced non–small cell lung cancer.

Dr. Harshman Discusses the Potential for New RCC Treatments

May 10th 2018

Lauren C. Harshman, MD, assistant professor of medicine, Harvard Medical School, senior physician, Dana-Farber Cancer Institute, discusses the potential for new treatment options in renal cell carcinoma.

Dr. Chase on the Standard of Care for Uterine Leiomyosarcoma

May 9th 2018

Dana Chase, MD, gynecologic oncologist, Arizona Oncology, discusses the standard of care for the treatment of patients with uterine leiomyosarcoma.

Dr. Paik on the Potential Approval of Lorlatinib for Patients With ALK-Positive NSCLC

May 9th 2018

Paul K. Paik, MD, clinical director of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of lorlatinib may alter the landscape for patients with ALK-positive non–small cell lung cancer (NSCLC).

Dr. Jacobs on the Efficacy of Ibrutinib and Acalabrutinib in Patients With MCL

May 9th 2018

Ryan W. Jacobs, MD, physician, Levine Cancer Institute, discusses the efficacy of ibrutinib (Imbruvica) and acalabrutinib (Calquence) in patients with mantle cell lymphoma (MCL).

Dr. Wistinghausen Discusses the Treatment of Pediatric NHL

May 9th 2018

Birte Wistinghausen, MD, medical director of the Division of Pediatric Hematology-Oncology, the Kravis Children's Hospital and Icahn School of Medicine at Mount Sinai, discusses the treatment of pediatric patients with non-Hodgkin lymphoma.

Dr. Essel Discusses Long-Term Bevacizumab in Ovarian Cancer

May 9th 2018

Kathleen Essel, MD, fellow, University of Oklahoma Health Science Center, discusses a study on the effects of long-term bevacizumab (Avastin) use in patients with ovarian cancer.

Dr. Goy Discusses the Evolution of Treatment for MCL

May 9th 2018

Andre Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses the evolving treatment landscape of mantle cell lymphoma.

Dr. Mark on the Use of Degarelix in Men With Prostate Cancer

May 8th 2018

James Ryan Mark, MD, assistant professor, Sidney Kimmel Cancer Center, Thomas Jefferson Hospital, discusses the use of degarelix (Firmagon) in the treatment of men with prostate cancer.